Dr Reddy's Laboratories Ltd banner

Dr Reddy's Laboratories Ltd
F:RDDA

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
F:RDDA
Watchlist
Price: 10.1 EUR
Market Cap: €1.7B

Wall St Price Targets

RDDA Price Targets Summary
Dr Reddy's Laboratories Ltd

Wall Street analysts forecast RDDA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RDDA is 11.92 EUR with a low forecast of 9.14 EUR and a high forecast of 15.99 EUR.

Lowest Forecast
Price Target
9.14 EUR
10% Downside
Average Forecast
Price Target
11.92 EUR
18% Upside
Highest Forecast
Price Target
15.99 EUR
58% Upside
Dr Reddy's Laboratories Ltd Competitors:
Price Targets
VTEX
VTEX
41% Upside
SYSR
Systemair AB
15% Upside

Revenue
Forecast

8% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
8% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 4 years is 8%.

Gross Profit
Forecast

8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
15%
Average Beat
8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
15%
Average Beat

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 4 years is 6%.

Operating Income
Forecast

6% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
6% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 4 years is 18%.

Pre-Tax Income
Forecast

7% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
7% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 2 years is 17%.

Net Income
Forecast

8% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
8% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 4 years is 16%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RDDA's stock price target?
Price Target
11.92 EUR

According to Wall Street analysts, the average 1-year price target for RDDA is 11.92 EUR with a low forecast of 9.14 EUR and a high forecast of 15.99 EUR.

What is the Revenue forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 4 years is 8%.

What is the Gross Profit forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 4 years is 6%.

What is the Operating Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 4 years is 18%.

What is the Pre-Tax Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 2 years is 17%.

What is the Net Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 4 years is 16%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett